Detalhe da pesquisa
1.
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med
; 378(19): 1789-1801, 2018 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658430
2.
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Lancet Oncol
; 16(13): 1389-98, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26433819
3.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657003
4.
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Lancet Oncol
; 14(3): 244-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23414588
5.
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Breast Cancer Res Treat
; 138(1): 149-55, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23378064
6.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Lancet Oncol
; 13(9): 869-78, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22884505
7.
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
J Clin Oncol
; 41(21): 3663-3669, 2023 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459755
8.
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Oncologist
; 17(4): 469-75, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22467666
9.
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet
; 375(9712): 377-84, 2010 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20113825
10.
Melanoma vasculogenic mimicry capillary-like structure formation depends on integrin and calcium signaling.
Microcirculation
; 18(5): 390-9, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21438962
11.
An attempt to prevent senescence: a mitochondrial approach.
Biochim Biophys Acta
; 1787(5): 437-61, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19159610
12.
Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma.
Can J Urol
; 16(4): 4726-32, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19671223
13.
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eur J Cancer
; 116: 148-157, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200321
14.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
N Engl J Med
; 353(16): 1659-72, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16236737
15.
Melanoma vasculogenic mimicry is strongly related to reactive oxygen species level.
Melanoma Res
; 17(6): 370-9, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17992120
16.
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Eur J Cancer
; 62: 62-75, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27208905
17.
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
J Clin Oncol
; 22(9): 1605-13, 2004 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15117982
18.
Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.
Immunol Lett
; 100(1): 88-93, 2005 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16055198
19.
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
J Natl Cancer Inst
; 106(1): djt337, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24317176
20.
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
J Clin Oncol
; 31(17): 2128-35, 2013 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23650416